Symposium 2026
Translating Human Genetics into Better Drug Development Decisions
DATE
Tuesday, October 20, 2026
TIME
13:00 – 15:00 EDT
VENUE
HoneyRose Hotel, 355 Blvd. De Maisonneuve Ouest, Montréal, Quebec H3A 1L6
The best medicines demand causal human biology.
THE CASE FOR HUMAN CAUSAL EVIDENCE
Genetic support raises a program's odds of success. AI accelerates it.
Agentified human causal biology is changing which programs drug developers can act on.
Disclosed partnerships include
WHAT WE DO
Not a vendor.
A capability.
Three associations in. One causal target out.
We support the decisions that shape programs and portfolios.
PROGRAM DECISIONS
Target Identification & Validation
We use causal human biology tools anchored in human genetics and AI to identify which targets are the actual cause of the disease.
Biomarkers
Identify the biomarkers that can act as pharmacodynamic read-outs of target engagement, or causal mediators using advanced AI-driven methods
Clinical Strategy & Trial Design
We identify the patient subgroups most likely to show a treatment effect.
PORTFOLIO DECISIONS
Portfolio Prioritization & Capital Allocation
AI-driven causal human biology tells you which programs to advance and which to stop.
In-Licensing and Transaction Diligence
THE DECISIONS THAT CHANGED WHAT HAPPENED NEXT
HOW WE DELIVER IT
Expert analysis. Decision-ready outputs.
Target and Disease Intelligence Reports
FOR GENETICS AND TRANSLATIONAL TEAMS
Full weight-of-evidence analyses with methods, results, and interpretation, structured around the decision your program needs to make.
Interactive Evidence Portals
FOR CROSS-FUNCTIONAL
EXPLORATION
Browser-based environments for exploring genetic evidence across targets, outcomes, and disease areas. Shareable across teams.
Analysis-Ready Data Tables
FOR BIOINFORMATICS AND DATA
SCIENCE
Structured outputs ready for internal teams to integrate into existing workflows, pipelines, and decision models.
Executive Decision Summaries
FOR BD, PORTFOLIO, AND BOARD
AUDIENCES
Decision-grade evidence packaged for BD meetings, board discussions, and investment decisions.
OUR IMPACT SINCE 2021
RETURNING PARTNER PROGRAMS
80%
of programs from returning partners
We generate evidence that teams use again and again.
PARTNERS
19+
across pharma, biotech, and venture
Trusted across the ecosystem.
SCIENTIFIC CREDIBILITY
240+
Credibility built over decades.